Sumitomo Dainippon Pharma Co. Ltd. and Takeda Pharmaceutical Company Limited Announce Decision to Terminate Their Agreement for the Joint Development and Exclusive Commercialization of Latuda® (lurasidone) - an Atypical Antipsychotic Agent, in Europe
Osaka, Japan (ots/PRNewswire) - Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon Pharma") (Head Office: Osaka, Japan: President: Masayo Tada) and Takeda Pharmaceutical Company Limited ("Takeda") (Head Office: Osaka, Japan: President and CEO: Christophe Weber) today jointly announced that their license ...
mehr